Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Sex influences susceptibility to methamphetamine cardiomyopathy in mice.

Marcinko MC, Darrow AL, Tuia AJ, Shohet RV.

Physiol Rep. 2019 Mar;7(6):e14036. doi: 10.14814/phy2.14036.

2.

Galectin-3 deficiency exacerbates hyperglycemia and the endothelial response to diabetes.

Darrow AL, Shohet RV.

Cardiovasc Diabetol. 2015 Jun 6;14:73. doi: 10.1186/s12933-015-0230-3.

3.

Mouse models and techniques for the isolation of the diabetic endothelium.

Darrow AL, Maresh JG, Shohet RV.

ISRN Endocrinol. 2013 Jun 11;2013:165397. doi: 10.1155/2013/165397. Print 2013.

4.

A thiocarbamate inhibitor of endothelial lipase raises HDL cholesterol levels in mice.

Greco MN, Connelly MA, Leo GC, Olson MW, Powell E, Huang Z, Hawkins M, Smith C, Schalk-Hihi C, Darrow AL, Xin H, Lang W, Damiano BP, Hlasta DJ.

Bioorg Med Chem Lett. 2013 May 1;23(9):2595-7. doi: 10.1016/j.bmcl.2013.02.113. Epub 2013 Mar 7.

PMID:
23528297
5.

Transcriptional analysis of the endothelial response to diabetes reveals a role for galectin-3.

Darrow AL, Shohet RV, Maresh JG.

Physiol Genomics. 2011 Oct 20;43(20):1144-52. doi: 10.1152/physiolgenomics.00035.2011. Epub 2011 Jul 26.

6.

Hypercholesterolemia potentiates aortic endothelial response to inhaled diesel exhaust.

Maresh JG, Campen MJ, Reed MD, Darrow AL, Shohet RV.

Inhal Toxicol. 2011 Jan;23(1):1-10. doi: 10.3109/08958378.2010.535572.

7.

A novel fluorogenic substrate for the measurement of endothelial lipase activity.

Darrow AL, Olson MW, Xin H, Burke SL, Smith C, Schalk-Hihi C, Williams R, Bayoumy SS, Deckman IC, Todd MJ, Damiano BP, Connelly MA.

J Lipid Res. 2011 Feb;52(2):374-82. doi: 10.1194/jlr.D007971.

8.

High-content assays for evaluating cellular and hepatic diacylglycerol acyltransferase activity.

Qi J, Lang W, Giardino E, Caldwell GW, Smith C, Minor LK, Darrow AL, Willemsens G, Dewaepenaert K, Roevens P, Linders JT, Liang Y, Connelly MA.

J Lipid Res. 2010 Dec;51(12):3559-67. doi: 10.1194/jlr.D008029. Epub 2010 Aug 28.

9.

NMR-based metabolomics of urine for the atherosclerotic mouse model using apolipoprotein-E deficient mice.

Leo GC, Darrow AL.

Magn Reson Chem. 2009 Dec;47 Suppl 1:S20-5. doi: 10.1002/mrc.2470.

10.

Integrated expressional analysis: application to the drug discovery process.

Ilyin SE, Horowitz D, Belkowski SM, Xin H, Eckardt AJ, Darrow AL, Chen C, Maley D, D'Andrea M, Plata-Salamán CR, Derian CK.

Methods. 2005 Nov;37(3):280-8.

PMID:
16308157
11.

An assay for sphingosine kinase activity using biotinylated sphingosine and streptavidin-coated membranes.

Roberts JL, Moretti PA, Darrow AL, Derian CK, Vadas MA, Pitson SM.

Anal Biochem. 2004 Aug 1;331(1):122-9.

PMID:
15246004
12.

Mer receptor tyrosine kinase signaling participates in platelet function.

Chen C, Li Q, Darrow AL, Wang Y, Derian CK, Yang J, de Garavilla L, Andrade-Gordon P, Damiano BP.

Arterioscler Thromb Vasc Biol. 2004 Jun;24(6):1118-23. Epub 2004 May 6.

PMID:
15130911
13.

Virus-based expression systems facilitate rapid target in vivo functionality validation and high-throughput screening.

Darrow AL, Conway KA, Vaidya AH, Rosenthal D, Wildey MJ, Minor L, Itkin Z, Kong Y, Piesvaux J, Qi J, Mercken M, Andrade-Gordon P, Plata-Salamán C, Ilyin SE.

J Biomol Screen. 2003 Feb;8(1):65-71.

PMID:
12854999
14.

A novel serine protease predominately expressed in macrophages.

Chen C, Darrow AL, Qi JS, D'Andrea MR, Andrade-Gordon P.

Biochem J. 2003 Aug 15;374(Pt 1):97-107.

15.

Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates.

Derian CK, Damiano BP, Addo MF, Darrow AL, D'Andrea MR, Nedelman M, Zhang HC, Maryanoff BE, Andrade-Gordon P.

J Pharmacol Exp Ther. 2003 Feb;304(2):855-61. Erratum in: J Pharmacol Exp Ther. 2003 Apr;305(1):402.

PMID:
12538843
16.

Mechanisms of protease-activated receptor-4 actions in cardiomyocytes. Role of Src tyrosine kinase.

Sabri A, Guo J, Elouardighi H, Darrow AL, Andrade-Gordon P, Steinberg SF.

J Biol Chem. 2003 Mar 28;278(13):11714-20. Epub 2003 Jan 8.

17.

The nucleotide-binding site of human sphingosine kinase 1.

Pitson SM, Moretti PA, Zebol JR, Zareie R, Derian CK, Darrow AL, Qi J, D'Andrea RJ, Bagley CJ, Vadas MA, Wattenberg BW.

J Biol Chem. 2002 Dec 20;277(51):49545-53. Epub 2002 Oct 18.

18.

Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats.

Andrade-Gordon P, Derian CK, Maryanoff BE, Zhang HC, Addo MF, Cheung Wm, Damiano BP, D'Andrea MR, Darrow AL, de Garavilla L, Eckardt AJ, Giardino EC, Haertlein BJ, McComsey DF.

J Pharmacol Exp Ther. 2001 Jul;298(1):34-42.

PMID:
11408522
19.

Protease-activated receptor-2 (PAR-2): structure-function study of receptor activation by diverse peptides related to tethered-ligand epitopes.

Maryanoff BE, Santulli RJ, McComsey DF, Hoekstra WJ, Hoey K, Smith CE, Addo M, Darrow AL, Andrade-Gordon P.

Arch Biochem Biophys. 2001 Feb 15;386(2):195-204.

PMID:
11368342
20.

Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor.

Andrade-Gordon P, Maryanoff BE, Derian CK, Zhang HC, Addo MF, Darrow AL, Eckardt AJ, Hoekstra WJ, McComsey DF, Oksenberg D, Reynolds EE, Santulli RJ, Scarborough RM, Smith CE, White KB.

Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12257-62.

21.

Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1.

Damiano BP, Cheung WM, Santulli RJ, Fung-Leung WP, Ngo K, Ye RD, Darrow AL, Derian CK, de Garavilla L, Andrade-Gordon P.

J Pharmacol Exp Ther. 1999 Feb;288(2):671-8.

PMID:
9918574
22.

Characterization of protease-activated receptor-2 immunoreactivity in normal human tissues.

D'Andrea MR, Derian CK, Leturcq D, Baker SM, Brunmark A, Ling P, Darrow AL, Santulli RJ, Brass LF, Andrade-Gordon P.

J Histochem Cytochem. 1998 Feb;46(2):157-64.

PMID:
9446822
23.

Protease-activated receptor-2 (PAR-2) is present in the rat hippocampus and is associated with neurodegeneration.

Smith-Swintosky VL, Cheo-Isaacs CT, D'Andrea MR, Santulli RJ, Darrow AL, Andrade-Gordon P.

J Neurochem. 1997 Nov;69(5):1890-6.

24.

Biological consequences of thrombin receptor deficiency in mice.

Darrow AL, Fung-Leung WP, Ye RD, Santulli RJ, Cheung WM, Derian CK, Burns CL, Damiano BP, Zhou L, Keenan CM, Peterson PA, Andrade-Gordon P.

Thromb Haemost. 1996 Dec;76(6):860-6.

PMID:
8972001
25.

Evidence for the presence of a protease-activated receptor distinct from the thrombin receptor in human keratinocytes.

Santulli RJ, Derian CK, Darrow AL, Tomko KA, Eckardt AJ, Seiberg M, Scarborough RM, Andrade-Gordon P.

Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9151-5.

26.

Preimplantation mouse embryos express a cell surface receptor for tissue-plasminogen activator.

Carroll PM, Richards WG, Darrow AL, Wells JM, Strickland S.

Development. 1993 Sep;119(1):191-8.

27.

Isolation of novel murine maternal mRNAs regulated by cytoplasmic polyadenylation.

Sallés FJ, Darrow AL, O'Connell ML, Strickland S.

Genes Dev. 1992 Jul;6(7):1202-12.

28.

Transient translational silencing by reversible mRNA deadenylation.

Huarte J, Stutz A, O'Connell ML, Gubler P, Belin D, Darrow AL, Strickland S, Vassalli JD.

Cell. 1992 Jun 12;69(6):1021-30.

PMID:
1606611
31.

Maintenance and use of F9 teratocarcinoma cells.

Darrow AL, Rickles RJ, Strickland S.

Methods Enzymol. 1990;190:110-7. No abstract available.

PMID:
1964999

Supplemental Content

Loading ...
Support Center